☰

Annie Umbricht - Publications

Affiliations: 
Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine, Baltimore, MD, United States 
Tree Info Grants Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Ware OD, Sweeney MM, Cunningham C, Umbricht A, Stitzer M, Dunn KE. Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial. Jama Network Open. 6: e232278. PMID 36920397 DOI: 10.1001/jamanetworkopen.2023.2278  0.348
2022 Sweeney MM, Prichett L, Fingerhood MI, Antoine D, Umbricht A, Dunn KE, Buresh ME. Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting. The American Journal On Addictions. PMID 35385169 DOI: 10.1111/ajad.13268  0.307
2019 Sweeney MM, Antoine DG, Nanda L, Géniaux H, Lofwall MR, Bigelow GE, Umbricht A. Increases in body mass index and cardiovascular risk factors during methadone maintenance treatment. Journal of Opioid Management. 15: 367-374. PMID 31849028 DOI: 10.5055/Jom.2019.0526  0.316
2019 Jarvis BP, Holtyn AF, DeFulio A, Koffarnus MN, Leoutsakos JS, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial. Drug and Alcohol Dependence. 197: 220-227. PMID 30852374 DOI: 10.1016/J.Drugalcdep.2018.12.026  0.365
2017 Jarvis BP, Holtyn AF, Berry MS, Subramaniam S, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults. Journal of Substance Abuse Treatment. PMID 28449955 DOI: 10.1016/J.Jsat.2017.04.012  0.383
2017 Jarvis B, Holtyn A, DeFulio A, Umbricht A, Fingerhood M, Bigelow G, Silverman K. Employment-based reinforcement of naltrexone adherence in unemployed heroin users: Effects on opiate use Drug and Alcohol Dependence. 171: e94. DOI: 10.1016/J.Drugalcdep.2016.08.265  0.343
2016 Jarvis BP, DeFulio A, Long L, Holtyn AF, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study. Journal of Substance Abuse Treatment. PMID 28161142 DOI: 10.1016/J.Jsat.2016.12.006  0.38
2016 Jarvis BP, Holtyn AF, DeFulio A, Dunn KE, Everly JJ, Leoutsakos JS, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults. Addiction (Abingdon, England). PMID 27936293 DOI: 10.1111/Add.13724  0.352
2015 Rass O, Umbricht A, Bigelow GE, Strain EC, Johnson MW, Mintzer MZ. Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence. Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors. 29: 237-46. PMID 25365653 DOI: 10.1037/Adb0000027  0.429
2015 Dunn K, DeFulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes. Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors. 29: 270-6. PMID 25134047 DOI: 10.1037/Adb0000010  0.458
2014 Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, Strain EC, Bigelow GE. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug and Alcohol Dependence. 140: 92-100. PMID 24814607 DOI: 10.1016/J.Drugalcdep.2014.03.033  0.414
2014 Umbricht A, Rass O, Bigelow G, Strain EC, Tompkins DA, Mintzer M. Correlates of drug use severity and HIV risk behaviors in cocaine- and opiate-dependent patients Drug and Alcohol Dependence. 140: e230. DOI: 10.1016/J.Drugalcdep.2014.02.637  0.36
2014 Umbricht A, Mintzer M, Rass O, Bigelow G, Johnson MW, Strain E, Tompkins DA. Correlates of impaired cognitive performance in cocaine- and opioid-dependent patients Drug and Alcohol Dependence. 140: e230. DOI: 10.1016/J.Drugalcdep.2014.02.636  0.335
2014 Rass O, Umbricht A, Bigelow G, Strain EC, Mintzer M. Topiramate impairs cognitive function in cocaine-dependent individuals maintained on methadone Drug and Alcohol Dependence. 140: e183. DOI: 10.1016/J.Drugalcdep.2014.02.512  0.421
2013 Dunn KE, Defulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Experimental and Clinical Psychopharmacology. 21: 74-83. PMID 23205722 DOI: 10.1037/A0030743  0.469
2012 Aklin WM, Severtson SG, Umbricht A, Fingerhood M, Bigelow GE, Lejuez CW, Silverman K. Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence. The Journal of Clinical Psychiatry. 73: e1056-61. PMID 22967782 DOI: 10.4088/Jcp.09M05807  0.37
2012 Henry PK, Umbricht A, Kleykamp BA, Vandrey R, Strain EC, Bigelow GE, Mintzer MZ. Comparison of cognitive performance in methadone maintenance patients with and without current cocaine dependence. Drug and Alcohol Dependence. 124: 167-71. PMID 22266090 DOI: 10.1016/J.Drugalcdep.2011.12.009  0.336
2012 DeFulio A, Everly JJ, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug and Alcohol Dependence. 120: 48-54. PMID 21782353 DOI: 10.1016/J.Drugalcdep.2011.06.023  0.488
2011 Vandrey R, Umbricht A, Strain EC. Increased blood pressure after abrupt cessation of daily cannabis use Journal of Addiction Medicine. 5: 16-20. PMID 21359104 DOI: 10.1097/Adm.0B013E3181D2B309  0.329
2011 Everly JJ, DeFulio A, Koffarnus MN, Leoutsakos JM, Donlin WD, Aklin WM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction (Abingdon, England). 106: 1309-18. PMID 21320227 DOI: 10.1111/J.1360-0443.2011.03400.X  0.477
2010 Walsh SL, Donny EC, Nuzzo PA, Umbricht A, Bigelow GE. Cocaine abuse versus cocaine dependence: Cocaine self-administration and pharmacodynamic response in the human laboratory Drug and Alcohol Dependence. 106: 28-37. PMID 19717246 DOI: 10.1016/J.Drugalcdep.2009.07.011  0.4
2009 Epstein DH, Schmittner J, Umbricht A, Schroeder JR, Moolchan ET, Preston KL. Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug and Alcohol Dependence. 101: 92-100. PMID 19101098 DOI: 10.1016/J.Drugalcdep.2008.11.006  0.368
2008 Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE. Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation. Psychopharmacology. 198: 149-58. PMID 18327673 DOI: 10.1007/S00213-008-1105-Z  0.362
2007 Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE. Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Addiction (Abingdon, England). 102: 1648-56. PMID 17854341 DOI: 10.1111/J.1360-0443.2007.01944.X  0.384
2005 Montoya ID, Schroeder JR, Preston KL, Covi L, Umbricht A, Contoreggi C, Fudala PJ, Johnson RE, Gorelick DA. Influence of psychotherapy attendance on buprenorphine treatment outcome. Journal of Substance Abuse Treatment. 28: 247-54. PMID 15857725 DOI: 10.1016/J.Jsat.2005.01.004  0.347
2004 Umbricht A, Huestis MA, Cone EJ, Preston KL. Effects of high-dose intravenous buprenorphine in experienced opioid abusers Journal of Clinical Psychopharmacology. 24: 479-487. PMID 15349002 DOI: 10.1097/01.Jcp.0000138766.15858.C6  0.321
2004 Preston KL, Umbricht A, Schroeder JR, Abreu ME, Epstein DH, Pickworth WB. Cyclazocine: comparison to hydromorphone and interaction with cocaine. Behavioural Pharmacology. 15: 91-102. PMID 15096909 DOI: 10.1097/00008877-200403000-00001  0.448
2004 Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, Fudala PJ. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmacology and Therapeutics. 75: 34-48. PMID 14749690 DOI: 10.1016/J.Clpt.2003.09.004  0.363
2003 Schroeder JR, Gupman AE, Epstein DH, Umbricht A, Preston KL. Do noncontingent vouchers increase drug use? Experimental and Clinical Psychopharmacology. 11: 195-201. PMID 12940498 DOI: 10.1037/1064-1297.11.3.195  0.306
2003 Epstein DH, Hawkins WE, Covi L, Umbricht A, Preston KL. Cognitive-behavioral therapy plus contingency management for cocaine use: Findings during treatment and across 12-month follow-up Psychology of Addictive Behaviors. 17: 73-82. PMID 12665084 DOI: 10.1037/0893-164X.17.1.73  0.331
2001 Preston KL, Umbricht A, Wong CJ, Epstein DH. Shaping cocaine abstinence by successive approximation Journal of Consulting and Clinical Psychology. 69: 643-654. PMID 11550730 DOI: 10.1037//0022-006X.69.4.643  0.304
2001 Pickens RW, Preston KL, Miles DR, Gupman AE, Johnson EO, Newlin DB, Soriano J, van den Bree MB, Umbricht A. Family history influence on drug abuse severity and treatment outcome. Drug and Alcohol Dependence. 61: 261-70. PMID 11164690 DOI: 10.1016/S0376-8716(00)00146-0  0.324
1995 Montoya ID, Umbricht A, Preston KL. Buprenorphine for human immunovirus-positive opiate-dependent patients Biological Psychiatry. 38: 135-136. PMID 7578651 DOI: 10.1016/0006-3223(95)00071-N  0.334
Show low-probability matches.